中草药-药物相互作用数据库的建立与评价方法探讨

doi:10.19803/j.1672-8629.20240182

摘要/Abstract

摘要： 目的介绍常用的草药-药物相互作用（HDI）数据库和评价方法,探讨中草药-药物相互作用（CHDI）的评价思路。方法检索中国知网和PubMed数据库建库至2024年3月19日数据,总结HDI数据库、因果关系推断、证据分级和质量评价,以及临床相关性的评价方法。结果临床决策支持（CDS）系统需要综合评估证据质量分级、临床相关性、风险因素、不良反应等参数;DI概率评估量表（DIPS）可用于评估HDI与不良事件的因果关系,但无专门针对HDI证据质量和临床相关性的评价方法。结论需参考药物相互作用质量评价方法以及中草药证据评价体系,建立CHDI证据评价体系和CDS工具。

关键词: 中草药-药物相互作用, 数据库, 因果关系推断, 证据质量, 临床相关性

Abstract: Objective To outline the commonly used databases and evaluation methods for Herb-Drug Interactions (HDIs) and explore ways to evaluate Chinese Herbal-Drug Interactions (CHDIs). Methods CNKI and PubMed were searched for related literature published from inception to March 19, 2024. The HDI database, causal inference, evidence grading and quality assessment, as well as methods for evaluation of clinical relevance were summarized. Results Clinical decision support (CDS) systems required all-round assessment of the quality grading of evidence, clinical relevance, risk factors and adverse reactions. The DIPS scale could be used to evaluate the causality between HDIs and adverse events, but there was no specific method for evaluating the quality of evidence and clinical relevance of HDIs. Conclusion The methods for evaluating the quality of drug interactions and the evaluation system for evidence of Chinese herbal medicine need to be consulted to establish an evidence evaluation system and CDS tool for CHDIs.

Key words: Chinese Herb-Drug Interaction, Database, Causal Inference, Evidence Quality, Clinical Correlation

中图分类号:

R969.2

申晨, 周娴, 刘建平. 中草药-药物相互作用数据库的建立与评价方法探讨[J]. 中国药物警戒, 2025, 22(8): 902-908.

SHEN Chen, ZHOU Xian, LIU Jianping. Database and Evaluation Methods for Chinese Herb-Drug Interactions[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 902-908.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240182

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I8/902

参考文献

[1] ADR, NMPA. National Annual Report on Adverse Drug Reaction Monitoring(2022)[EB/OL].[2024-02-26]. https://cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_sjbg/202303/t20230324_50019.html.
[2] HAMMAR T, HAMQVIST S, ZETTERHOLM M, et al.Current Knowledge about Providing Drug-Drug Interaction Services for Patients-a Scoping rReview[J]. Pharmacy (Basel), 2021, 9(2): 69.
[3] LIU R, ABDULHAMEED MDM, KUMAR K, et al.Data-Driven Prediction of Adverse Drug Reactions Induced by Drug-Drug Interactions[J]. BMC Pharmacol Toxicol, 2017, 18(1): 44.
[4] CHEN W, MOU JZ, SA RN, et al.Establishment of Pharmaceutical Care Pathway for Tumor Patients Treated with Integrated Traditional Chinese and Western Medicine[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2020, 20(5): 628-630.
[5] CLAIRET AL, BOITEUX-JURAIN M, CURTIT E, et al.Interaction Between Phytotherapy and Oral Anticancer Agents: Prospective Study and Literature Review[J]. Med Oncol, 2019, 36(5): 45.
[6] ZHANG Y, MAN IP C, LAI YS, et al.Overview of Current Herb-Drug Interaction Databases[J]. Drug Metab Dispos, 2022, 50(1): 86-94.
[7] SCHEIFE RT, HINES LE, BOYCE RD, et al.Consensus Recommen-Dations for Systematic Evaluation of Drug-Drug Interaction Evidence for Clinical Decision Support[J]. Drug Saf, 2015, 38(2): 197-206.
[8] WANG L, TAFJORD O, COHAN A, et al.SUPP.AI: Finding Evidence for Supplement-Drug Interactions[C]. Proceedings of the 58th Annual Meeting of the Association for Computational Linguistics: System Demonstrations, 2020: 362-371.
[9] PAN HY, WU LW, WANG PC, et al.Real-World Evidence of the Herb-Drug Interactions[J]. J Food Drug Anal, 2022, 30(3): 316-330.
[10] BABOS MB, HEINAN M, REDMOND L, et al.Herb-Drug Interactions: Worlds Intersect with the Patient at the Center[J]. Medicines (Basel), 2021, 8(8): 44.
[11] BIASE TMMA, BRUNIÉRI GS, SILVA MT, et al. Potential Drug Interactions in Adults living in Manaus: a Real-World Comparison of Two Databases, 2019[J]. Turk J Pharm Sci, 2022, 19(5): 543-551.
[12] SHAREEF J, BELAGODU SRIDHAR S, THOMAS S, et al.Potential Psychotropic and COVID-19 Drug Interactions: a Comparison of Integrated Evidence from Six Database Programs[J]. Cureus, 2021, 13(12): e20319.
[13] BECKETT RD, BRATTAIN Y, TRUONG J, et al.Tertiary Drug Information Sources for Treatment and Prevention of COVID-19[J]. J Med Libr Assoc, 2023, 111(4): 783-791.
[14] SILE I, TETEROVSKA R, ONZEVS O, et al.Safety Concerns Related to the Simultaneous Use of Prescription or Over-the-Counter Medications and Herbal Medicinal Products: Survey Results Among Latvian Citizens[J]. Int J Environ Res Public Health, 2023, 20(16): 6551.
[15] LEDGER TS, BROOKE-COWDEN K, COIERA E.Post-Implementation Optimization of Medication Alerts in Hospital Computerized Provider Order Entry Systems: a Scoping Review[J]. J Am Med Inform Assoc, 2023, 30(12): 2064-2071.
[16] GAO YJ, ZHAO X, BAI TK, et al.Discovery and Identification Strategies of Drug Safety Risks Based on Big Data Monitoring of Adverse Reactions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(1): 1-5, 14.
[17] NARANJO CA, BUSTO U, SELLERS EM, et al.A Method for Estimating the Probability of Adverse DrugReactions[J]. Clin Pharmacol Ther, 1981, 30: 239-245.
[18] RODRÍGUEZ-LOPEZ A, MEJÍA-ABRIL G, ZUBIAUR P, et al. Use of Exposure Data to Establish Causality in Drug-Adverse Event Relationships: an Example with Desvenlafaxine[J]. Pharmaceuticals (Basel), 2024, 17(1): 69.
[19] PRADHAN P, LAVALLEE M, AKINOLA S, et al.Causality Assessment of Adverse Drug Reaction: a Narrative Review to Find the Most Exhaustive and Easy-to-Use Tool in Post-Authorization Settings[J]. J Appl Biomed, 2023, 21(2): 59-66.
[20] SHARMA JB, KRISHNAMURTHY MN, AWASE A, et al.Validation of a Novel Causality Assessment Scale for Adverse Events in Non-small Cell Lung Carcinoma Patients Treated with Platinum and Pemetrexed Doublet Chemotherapy[J]. Ther Adv Drug Saf, 2021, 12: 2042098621991280.
[21] HORN JR, HANSTEN PD, CHAN LN.Proposal for a New Tool to Evaluate Drug Interaction Cases[J]. Ann Pharmacother, 2007, 41(4): 674-680.
[22] ALGHAMDI W, AL-FADEL N, ALGHAMDI EA, et al.Signal Detection and Assessment of Herb-Drug Interactions: Saudi Food and Drug Authority Experience[J]. Drugs Real World Outcomes, 2023, 10(4): 577-585.
[23] SHU D, HAN P, HENNESSY S, et al.Robust Causal Inference of Drug-Drug Interactions[J]. Stat Med, 2023, 42(7): 970-992.
[24] BÖTTIGER Y, LAINE K, ANDERSSON ML, et al. SFINX-a Drug-Drug Interaction Database Designed for Clinical Decision Support Systems[J]. Eur J Clin Pharmacol, 2009, 65(6): 627-633.
[25] VAN ROON EN, FLIKWEERT S, LE COMTE M, et al.Clinical Relevance of Drug-Drug Interactions: a Structured Assessment Procedure[J]. Drug Saf, 2005, 28(12): 1131-1139.
[26] GUYATT GH, OXMAN AD, VIST GE, et al.GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of Recommend-ations[J]. BMJ, 2008, 336(7650): 924-926.
[27] The University of Liverpool. Quality of Evidence[EB/OL].[2024-02-26]. https://liverpool-hiv-hep.s3.eu-west-2.amazonaws.com/QoE_Info_HIV_2023_Jan.pdf.
[28] SEDEN K, GIBBONS S, MARZOLINI C, et al.Development of an Evidence Evaluation and Synthesis System for Drug-Drug Interactions, and Its Application to a Systematic Review of HIV and Malaria Coinfection[J]. PLoS One, 2017, 12(3): e0173509.
[29] The University of Liverpool. Interaction Summary Tables[EB/OL].[2024-02-26]. https://www.hep-druginteractions.org/prescribing_resources/.
[30] The University of Liverpool. Interaction Summary Tables[EB/OL].[2024-02-26]. https://www.hiv-druginteractions.org/prescribing_resources.
[31] XIAO XH, LUO Y, ZHAO X, et al.New Strategies and Methods for Evaluating the Efficacy of Traditional Chinese Medicine: Integrated Evidence Chain Method[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2024, 49(19): 5113-5124.
[32] LIU SN, GUO XF WU DR, et al. Discussion on the Construction of a Clinical Evidence Grading System for Traditional Chinese Medicine Interventions[J]. Journal of Traditional Chinese Medicine(中医杂志), 2023(18): 1885-1889.
[33] ZHANG L, ZENG XT, TONG L.The Approach to Developing a Grading Scale for Evidence Evaluation in Traditional Chinese Medicine Based on Evidence-Based Medicine Principles[J]. Chinese Archives of Traditional Chinese Medicine(中华中医药杂志), 2020, 35(6): 2971-2973.
[34] ORELLANA-PAUCAR A, VINTIMILLA-ROJAS D.Interactions of Clinical Relevance Associated with Concurrent Administration of Prescription Drug and Food or Medicinal Plants: a Systematic Review Protocol[J]. Syst Rev, 2020, 9(1): 1.
[35] FASINU PS, RAPP GK.Herbal Interaction with Chemotherapeutic Drugs-a Focus on Clinically Significant Findings[J]. Front Oncol, 2019, 9: 1356.
[36] SHAIKH AS, THOMAS AB, CHITLANGE SS.Herb-Drug Interaction Studies of Herbs Used in Treatment of Cardiovascular Disorders-a Narrative Review of Preclinical and Clinical Studies[J]. Phytother Res, 2020, 34(5): 1008-1026.
[37] European Medicines Agency.Guideline on the Investigation of Drug Interactions[EB/OL].[2024-03-29].https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.
[38] DE LEON J, SPINA E, DIAZ FJ.Pharmacokinetic Drug Interaction Studies Must Consider Pharmacological Heterogeneity, Use of Repeated Dosing, and Translation Into a Message Understandable to Practicing Clinicians[J]. J Clin Psychopharmacol, 2009, 29(3): 201-205.
[39] YU LX, JIANG W, ZHANG X, et al.Novel Bioequivalence Approach for Narrow Therapeutic Index Drugs[J]. Clin Pharmacol Ther, 2015, 97(3): 286-291.